Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic Agents

Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic AgentsПодробнее

Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast CancerПодробнее

Dr. Joyce O'Shaughnessy on Treatment With Everolimus in Advanced Breast CancerПодробнее

Dr. O'Shaughnessy on the Future of TNBC TreatmentПодробнее

Breast Cancer (Carcinoma) #doctor #chemotherapy #camcer #viralvideo #carcinoma #breastcancerПодробнее

Dr. O'Shaughnessy on the Future of Breast Cancer TreatmentПодробнее

Dr. Joyce O’Shaughnessy on Promising Agents in Triple-Negative Breast CancerПодробнее

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast CancerПодробнее

Joyce O'Shaughnessy, MD explains the importance of The School of Breast OncologyПодробнее

Headline News in Breast Cancer with Dr. Joyce O'ShaughnessyПодробнее

Joyce O’Shaughnessy, MD: Main Indications for Dose Reduction With EribulinПодробнее

Molecular Re-classification of Breast Cancer – Part 2: Joyce O'ShaughnessyПодробнее

Joyce O’Shaughnessy, MD: Candidacy for Eribulin TherapyПодробнее

Dr. O'Shaughnessy Discusses Negative TNBC Iniparib Trial ResultsПодробнее

Dr. O'Shaughnessy on the Future of Breast Cancer BiomarkersПодробнее

Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast CancerПодробнее

Combination Immunotherapy Appears Promising in Breast Cancer SubtypesПодробнее

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast CancerПодробнее

Dr. O'Shaughnessy on Role of Chemotherapy in Future TNBC TreatmentПодробнее

Joyce O’Shaughnessy, MD: Principle Third-Line Options for Patients With Metastatic TNBCПодробнее